Aortic Stenosis
Calcium · Gradient · TAVR — From Murmur Detection to Valve Replacement
Aortic stenosis (AS) is the most common valvular disease requiring intervention in the developed world, affecting approximately 2–3% of adults over age 75.[1] The dominant etiology in Western countries is calcific degeneration of a tricuspid (or bicuspid) aortic valve — not rheumatic disease. The cardinal pathophysiologic event is progressive left ventricular pressure overload from a narrowing, calcified outflow tract. Once symptoms emerge — angina, syncope, or dyspnea — median survival without aortic valve replacement is less than 2–3 years. The last decade has been defined by TAVR (transcatheter aortic valve replacement), which expanded from inoperable patients in 2010 to low-risk patients by 2019, making definitive valve therapy accessible to nearly all patients with severe AS.
For most of the 20th century, severe aortic stenosis was managed surgically — or not at all. Surgical aortic valve replacement (SAVR), pioneered in the 1960s following the advent of cardiopulmonary bypass, transformed AS from a near-universally fatal disease into a treatable one. By the 1990s, SAVR was the unquestioned standard of care, but a large population of older or frail patients — deemed too high-risk for open-heart surgery — had no viable option and faced median survival of months once symptoms appeared.[1]
The first percutaneous transcatheter aortic valve implantation in a human was performed by Alain Cribier in Rouen, France in April 2002 in a patient too ill for surgery. Eight years later, the landmark PARTNER 1B trial (2010) randomized 358 inoperable patients with severe AS to transfemoral TAVR or optimal medical therapy (including balloon aortic valvuloplasty).[2] TAVR reduced all-cause mortality at 1 year from 50.7% to 30.7% — a 20% absolute risk reduction. The conclusion was definitive: TAVR offered a survival benefit where none had previously existed.
PARTNER 1A (2011) then compared TAVR head-to-head against SAVR in high-risk surgical candidates (STS predicted operative mortality ≥10%), demonstrating non-inferiority in 1-year mortality (24.2% vs. 26.8%).[3] The field then expanded TAVR into intermediate-risk patients. PARTNER 2A (2016) showed non-inferiority to SAVR in patients with STS scores of 4–8% at 2 years.[4] The SURTAVI trial (2017), using the self-expanding CoreValve system in a similar intermediate-risk population, confirmed non-inferiority at 24 months with numerically lower stroke rates with TAVR.[5]
The final frontier fell in 2019. PARTNER 3 randomized 1,000 low-risk patients (STS <4%) to transfemoral TAVR with the Sapien 3 balloon-expandable valve versus SAVR.[6] At 1 year, the composite of death, stroke, or rehospitalization was significantly lower with TAVR (8.5% vs. 15.1%). TAVR had not merely caught up to surgery — it was superior in low-risk patients. Today, transfemoral TAVR is the preferred approach for most patients with severe symptomatic AS when anatomy is suitable, regardless of surgical risk.
AS results from progressive calcification and fibrosis of aortic valve leaflets, reducing leaflet excursion and narrowing the effective orifice area.[1] The left ventricle responds to fixed outflow obstruction with concentric hypertrophy — increasing wall thickness to normalize wall stress (LaPlace's law) and preserve stroke volume. This compensatory response can be sustained for years to decades, during which the patient is "asymptomatic" but undergoing ongoing LV remodeling and myocardial fibrosis.
As the valve area falls below ~1.0 cm² (or indexed AVA <0.6 cm²/m²), compensatory capacity is eventually exceeded and three cardinal symptoms emerge: angina (demand ischemia from the hypertrophied LV with compressed subendocardial coronaries), syncope (inability to augment cardiac output during exercise as peripheral vasodilation outpaces fixed flow), and exertional dyspnea or heart failure (rising LVEDP from diastolic dysfunction and eventual systolic failure).[1] Each symptom carries a distinct natural history without definitive intervention: angina confers a mean survival of approximately 5 years, syncope 3 years, and heart failure 1–2 years.
The natural history of truly asymptomatic severe AS is more nuanced than once believed. Among 622 adults with hemodynamically significant asymptomatic AS followed for a mean of 5.4 years, only 33% remained free of cardiac symptoms at 5 years, and the probability of remaining free of surgery or cardiac death was just 25% at 5 years.[7] Yet the annualized risk of sudden death in truly asymptomatic patients remains below 1% per year — generally less than the procedural risk of elective AVR at experienced centers — which is why watchful waiting with close surveillance remains the standard for most asymptomatic patients.
Low-flow, low-gradient (LFLG) severe AS is an important and frequently underdiagnosed phenotype. Two variants exist: (1) Classic LFLG-rEF (EF <50%): The LV has failed and cannot generate adequate transvalvular gradient even across a severely calcified valve. Dobutamine stress echocardiography differentiates true severe AS (AVA remains <1.0 cm² at peak contractile stimulation) from "pseudosevere" AS (AVA normalizes to >1.0 cm² as contractility improves). (2) Paradoxical LFLG-pEF (EF ≥50%): A small, hypertrophied LV with disproportionately reduced stroke volume index (<35 mL/m²) despite preserved EF — common in elderly women. CT calcium scoring (≥2,000 AU in men, ≥1,200 AU in women) confirms true severe calcific AS when Doppler gradients are deceptively low.
The ACC/AHA 2020 guideline uses a 4-stage classification (A through D) based on valve morphology, hemodynamics, and symptoms. Echocardiographic severity is graded primarily by peak jet velocity (Vmax), mean gradient, and AVA by the continuity equation.[1]
| Stage | Vmax (m/s) | Mean ΔP (mmHg) | AVA (cm²) | Notes |
|---|---|---|---|---|
| A — At Risk | Normal | Normal | Normal | Bicuspid AV, ESRD, prior RHD |
| B — Progressive (mild–mod) | 2.0–3.9 | <40 | >1.0 cm² | Asymptomatic; echo q1–5yr by severity |
| C1 — Severe Asymptomatic (LVEF ≥50%) | ≥4.0 | ≥40 | ≤1.0 | Watchful waiting; exercise test; yearly echo |
| C2 — Severe Asymptomatic (LVEF <50%) | ≥4.0 | ≥40 | ≤1.0 | AVR recommended even without symptoms |
| D — Severe Symptomatic | ≥4.0 (may be lower in LFLG) | ≥40 (may be lower in LFLG) | ≤1.0 | Angina, syncope, or HF — AVR indicated Class I |
Do not vasodilate. Patients with severe AS have fixed obstruction and are exquisitely preload-dependent. Nitroglycerin, ACE inhibitors, dihydropyridine calcium channel blockers, and other vasodilators can precipitate catastrophic hemodynamic collapse by reducing preload and afterload in an LV that depends on adequate filling pressure to force output through a fixed obstruction. If the patient presents in cardiogenic shock or acute decompensation, the priorities are emergent valve team consultation and hemodynamic stabilization — balloon aortic valvuloplasty (BAV) can temporize hemodynamics as a bridge to definitive TAVR or SAVR. Diuretics should be used cautiously and judicious volume may paradoxically be needed if the patient is excessively diuresed.
The hallmark of AS is a harsh, crescendo-decrescendo systolic murmur at the right upper sternal border (2nd intercostal space) with radiation to the carotids.[1] Key principle: the later the peak of the murmur within systole, the more severe the stenosis. Additional findings reflect the hemodynamic burden of LV pressure overload. Note the Gallavardin phenomenon: high-frequency components of the AS murmur can radiate to the cardiac apex and mimic a separate mitral regurgitation murmur.
| Finding | Sensitivity | Specificity | Clinical Pearl |
|---|---|---|---|
| Crescendo-decrescendo systolic murmur (RUSB, 2nd ICS) | ~90% | Moderate | Late-peaking = more severe; soft murmur in low-flow AS ≠ mild disease |
| Radiation to carotids | ~75% | Moderate | High-velocity turbulent jet transmitted up great vessels |
| Pulsus parvus et tardus | ~50–65% | High | Slow-rising, weak carotid upstroke; more specific for severe AS |
| Absent or diminished A2 | ~50% | ~80% | Calcified immobile leaflets cannot close audibly; S2 becomes single |
| S4 gallop | ~60% | Moderate | Atrial kick into stiff hypertrophied LV; indicates elevated LVEDP |
| Paradoxical S2 split | Uncommon | High | Delayed LV ejection; specific for severe or critical AS |
Parasternal long-axis (PLAX). Assess leaflet thickening, echogenicity (calcification), and excursion. Echodense, barely-opening leaflets in systole are highly suggestive of significant AS. Measure LVOT diameter at 0.5–1 cm below the annulus (inner edge to inner edge) — this measurement is squared in the continuity equation, so precision matters.
Parasternal short-axis (PSAX) at AV level. Identifies valve morphology (bicuspid vs. tricuspid; fused raphae and eccentric closure = bicuspid). Direct planimetry of valve area is possible but technically challenging at bedside.
Apical 5-chamber (A5C) — CW Doppler. Align the CW beam parallel to the AV jet. Measure peak velocity (Vmax ≥4 m/s = severe) and trace the full envelope to obtain mean gradient (≥40 mmHg = severe). Also attempt the right parasternal window (patient in right lateral decubitus) — this often yields the highest, most accurate transaortic velocity and is frequently missed at bedside.
Continuity equation for AVA. AVA = (LVOT CSA × LVOT VTI) ÷ AV VTI. LVOT area = π × (LVOT diameter ÷ 2)². At bedside, the Doppler Velocity Index (DVI = LVOT VTI ÷ AV VTI) is simpler: DVI <0.25 = severe AS without needing formal AVA.[8]
LV assessment. Concentric hypertrophy (increased relative wall thickness >0.42, normal or small cavity), hyperdynamic function, and restricted AV excursion in a dyspneic elderly patient makes AS the unifying diagnosis until proven otherwise. Also assess diastolic dysfunction (E/A, E/e') and TR jet for pulmonary pressure estimation.
BNP/NT-proBNP is elevated even in ostensibly asymptomatic severe AS and tracks disease severity. A rising BNP on serial assessments predicts imminent symptom development and may prompt earlier intervention consideration. Elevated hs-troponin in AS reflects myocardial fibrosis rather than acute coronary disease and is an early biomarker of irreversible myocardial injury.[1]
ECG typically shows LV hypertrophy (Sokolow-Lyon criteria: S in V1 + R in V5 or V6 ≥35 mm) with lateral repolarization changes ("strain" pattern: ST depression and T-wave inversions in I, aVL, V5-6). New atrial fibrillation in severe AS is hemodynamically significant — the loss of atrial kick in a stiff, non-compliant LV can precipitate decompensation.
Cardiac CT serves two critical purposes: (1) CT calcium scoring of the aortic valve — the most reliable adjudicator of AS severity when Doppler is discordant or gradients are low-flow (AV calcium score ≥2,000 AU in men or ≥1,200 AU in women confirms severe calcific AS); and (2) pre-procedural TAVR planning — annular measurements for prosthesis sizing, iliofemoral access vessel assessment, and coronary ostial heights to anticipate coronary obstruction risk.
Coronary angiography or CT coronary angiography is indicated before planned AVR. Coexistent significant CAD is present in 40–60% of patients with severe AS; concomitant revascularization is performed at the time of SAVR or staged with TAVR as needed.
Exercise stress testing in truly asymptomatic severe AS is safe when supervised and underused clinically. It can unmask occult symptoms, an abnormal BP response (failure to rise ≥20 mmHg), or poor exercise tolerance — each of which constitutes an indication for earlier AVR. Never perform in symptomatic severe AS.
| Intervention | When & How | Evidence & Key Points |
|---|---|---|
| No medical therapy to slow AS progression | No agent proven to alter natural history; treat cardiovascular risk factors per standard guidelines | SEAS (2008): intensive lipid lowering with simvastatin/ezetimibe vs. placebo in 1,873 patients with mild-moderate AS showed no reduction in AS progression or major valve events despite reducing ischemic cardiovascular events.[9] Statins, ACE inhibitors, and ARBs are not indicated to slow AS progression. |
| Surgical AVR (SAVR) | Symptomatic severe AS in surgical candidates; preferred for bicuspid AV in younger patients (<65–70), concomitant coronary or aortic surgery, or anatomy unfavorable for TAVR | Gold standard for decades. PARTNER 1A established non-inferiority of TAVR vs. SAVR in high-risk patients.[3] Mechanical valves (warfarin lifelong) preferred in patients <65; bioprosthetic valves for patients ≥65 or with anticoagulation contraindications. Operative mortality at experienced centers: ~1–2% for low-risk patients.[8] |
| Transcatheter AVR (TAVR) | Symptomatic severe AS in all surgical risk groups when transfemoral anatomy is suitable; preferred over SAVR for most patients age ≥75 | PARTNER 1B: 20% absolute mortality reduction vs. medical therapy in inoperable patients.[2] PARTNER 1A: non-inferior to SAVR in high risk.[3] PARTNER 2A and SURTAVI: non-inferior in intermediate risk.[4][5] PARTNER 3: superior composite endpoint in low risk (8.5% vs. 15.1% at 1 yr).[6] Key risks: stroke (~2–4%), pacemaker implantation (5–25% with self-expanding valves), paravalvular regurgitation, vascular access complications. |
| Early AVR for asymptomatic severe AS | Consider in: Vmax ≥5 m/s, LVEF <50%, exercise-induced hypotension/symptoms, rapid hemodynamic progression, or very low surgical risk with patient preference | AVATAR (2022): early AVR vs. watchful waiting in asymptomatic severe AS (Vmax ≥4 m/s, LVEF ≥50%, STS <10%) — early surgery reduced composite of death, MI, stroke, or unplanned HF hospitalization (HR 0.46, 95% CI 0.23–0.90).[10] ACC/AHA 2020 currently rates early AVR Class IIb for asymptomatic severe AS; evidence is evolving toward IIa as trial data accumulate.[8] |
| Balloon aortic valvuloplasty (BAV) | Bridge to definitive AVR in hemodynamically unstable or critically ill patients; not a definitive therapy | Rapidly reduces gradient and can stabilize cardiogenic shock or critical AS complicating non-cardiac surgery. Effect is temporary — valve re-stenoses within 6–12 months. Reserved for hemodynamic rescue pending definitive valve replacement.[8] |
| Recommendation — ACC/AHA 2020 VHD Guideline[8] | Class | LOE |
|---|---|---|
| AVR is recommended in symptomatic patients with severe high-gradient AS (Stage D1), regardless of LVEF or surgical risk | I | B-R |
| AVR is recommended in asymptomatic patients with severe AS (Stage C2) and LVEF <50% | I | B-NR |
| TAVR is recommended over SAVR in patients ≥80 years or with life expectancy <10 years and suitable transfemoral anatomy | I | A |
| AVR is reasonable in asymptomatic very severe AS (Stage C1, Vmax ≥5 m/s) and low surgical risk | IIa | B-NR |
| AVR is reasonable in asymptomatic severe AS with exercise-induced hypotension or symptoms on stress testing | IIa | B-NR |
| AVR is reasonable in asymptomatic severe AS with rapid hemodynamic progression (>0.3 m/s/yr) and low surgical risk | IIa | C-LD |
| AVR may be considered in asymptomatic severe AS (Vmax 4.0–4.9 m/s, LVEF ≥50%) when operative mortality <1% | IIb | C-LD |
| Medical therapy (statins, RAAS agents) should NOT be used to reduce hemodynamic progression of AS | III: No Benefit | A |
LFLG AS is the most diagnostically challenging syndrome in structural heart disease. The apparent paradox: AVA <1.0 cm² but mean gradient <40 mmHg. Two completely different mechanisms produce this Doppler pattern, and their management strategies differ substantially.
Classic LFLG (EF <50%) — The LV has failed. Reduced contractility lowers effective orifice area in a "pseudosevere" valve (only appears severe due to low flow), OR the valve is truly severely calcified but the failing LV cannot generate adequate flow velocity. The test: low-dose dobutamine stress echo (5–20 mcg/kg/min). If contractile reserve exists (stroke volume increases ≥20%), a truly severe valve stays narrow (AVA <1.0 cm² at peak dose); pseudosevere AS opens up (AVA rises to >1.0 cm²). CT calcium score >2,000 AU in men confirms true calcific severe AS when dobutamine echo is inconclusive. AVR in confirmed true classic LFLG AS carries higher procedural risk but offers meaningful survival benefit — TAVR is preferred given reduced EF.
Paradoxical LFLG (EF ≥50%) — The LV is small and hypertrophied with such efficient emptying that it generates only moderate flow velocity across even a truly severe valve. Stroke volume index is <35 mL/m² despite EF ≥50%. The diagnosis is confirmed by CT calcium score ≥1,200 AU in women (≥2,000 AU in men) — the most reliable approach in this group. These patients are often more symptomatic than they report, and subtly so. AVATAR data included patients with exactly this phenotype and showed benefit from early AVR.[10]
The practical bottom line: when the gradient appears "mild" but the AVA is <1.0 cm² and the clinical picture doesn't fit, don't stop at the Doppler numbers. Obtain a CT calcium score. The ACC/AHA 2020 guideline gives a Class IIa recommendation for AVR in symptomatic LFLG AS with evidence of true severe disease.[8]
358 inoperable severe AS patients randomized to transfemoral TAVR vs. standard therapy. TAVR reduced 1-year all-cause mortality from 50.7% to 30.7%, establishing TAVR as a lifesaving therapy where none previously existed.
1,000 low-risk patients randomized to Sapien 3 TAVR vs. SAVR. TAVR achieved significantly lower composite of death, stroke, or rehospitalization at 1 year (8.5% vs. 15.1%), establishing TAVR as preferred in low-risk patients.
157 asymptomatic severe AS patients randomized to early AVR vs. watchful waiting. Early surgery reduced the composite of CV death, acute MI, stroke, or HF hospitalization (HR 0.46), providing the strongest RCT evidence for early intervention in this population.
Comprehensive guideline covering AS staging (A–D), echocardiographic criteria, surgical vs. transcatheter decision-making, timing of intervention, LFLG evaluation algorithm, and valve type selection for SAVR.
[1] Nishimura RA. Aortic Valve Disease. In: Fuster V, Harrington RA, Narula J, Eapen ZJ, eds. Hurst and Fuster's The Heart, 15th ed. McGraw-Hill, 2022.
[2] Leon MB, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery (PARTNER 1B). N Engl J Med. 2010;363(17):1597–1607. PMID: 20961243. [PubMed]
[3] Smith CR, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients (PARTNER 1A). N Engl J Med. 2011;364(23):2187–2198. PMID: 21639811. [PubMed]
[4] Leon MB, et al. Transcatheter aortic-valve replacement in intermediate-risk patients (PARTNER 2A). N Engl J Med. 2016;374(17):1609–1620. PMID: 27040324. [PubMed]
[5] Reardon MJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients (SURTAVI). N Engl J Med. 2017;376(14):1321–1331. PMID: 28304219. [PubMed]
[6] Mack MJ, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients (PARTNER 3). N Engl J Med. 2019;380(18):1695–1705. PMID: 30883058. [PubMed]
[7] Pellikka PA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005;111(24):3290–3295. PMID: 15956131. [PubMed]
[8] Otto CM, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 2021;77(4):e25–e197. PMID: 33342586. [PubMed]
[9] Rossebø AB, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (SEAS). N Engl J Med. 2008;359(13):1343–1356. PMID: 18765433. [PubMed]
[10] Banovic M, et al. Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis (AVATAR). Circulation. 2022;145(7):648–658. PMID: 34779220. [PubMed]